Discovery of hydrazone derivatives as novel STAT3 antagonists against pancreatic and colorectal cancers
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Hsin-Yu Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of BioPharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Antineoplastic Agents, Hydrazones, Colorectal Neoplasms. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Executive Yuan Republic of China Ministry of Education, National Sun Yat-sen University, National Science and Technology Council.
Abstract (Originalsprache)
Signal transducer and activator of transcription 3 (STAT3) has been an anti-cancer protein target for three decades due to its over-activation in various cancers; however, direct STAT3 inhibitors have not reached the market. In this study, a series of novel hydrazone derivatives were designed, synthesized, and characterized. The most promising compound P42 was found to selectively target the STAT3 SH2 domain over the DNA-binding domain, as suggested by the results from fluorescence polarization assays. The GI50 values after 72 h of P42 treatment were determined to be 0.85-5 μM in STAT3-overexpressing pancreatic and colorectal cancer cell lines harboring KRAS mutations (MIA PaCa-2, DLD-1 and HCT 116). Western blot analyses showed that P42 significantly inhibited phosphorylated STAT3 levels without affecting total STAT3 and its upstream kinases JAK2 and SRC. P42 demonstrated significant autophagy-associated cell death rather than apoptosis or necrosis in flow cytometry analyses, with increases in LC3II/I ratios and decreases in p62 levels. Cancer stemness potential was significantly abrogated with P42 as shown in colony formation assay and decreases in epithelial-mesenchymal transition/stemness markers SNAIL and ZEB1 levels. Molecular docking further supported a plausible binding mode within the STAT3 SH2 domain for P42, and SwissADME prediction suggested its favorable drug-likeness properties. Taken together, P42 warrants future anti-cancer drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of BioPharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
- Institute of BioPharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Electronic address: po-chang.shih.23@mail.nsysu.edu.tw.
Förderung
- Executive Yuan Republic of China Ministry of Education
- National Sun Yat-sen University
- National Science and Technology Council
Zitieren
APA
Yang, H. Y., Chiu, M. H., & Shih, P. C. (2026). Discovery of hydrazone derivatives as novel STAT3 antagonists against pancreatic and colorectal cancers. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110293
Vancouver
Yang HY, Chiu MH, Shih PC. Discovery of hydrazone derivatives as novel STAT3 antagonists against pancreatic and colorectal cancers. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110293
BibTeX
@article{Yang2026,
author = {Yang, Hsin-Yu and Chiu, Min-Hua and Shih, Po-Chang},
title = {Discovery of hydrazone derivatives as novel STAT3 antagonists against pancreatic and colorectal cancers},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110293}
}
EUVIMED